Scrip is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Pfizer And Shionogi Form Vanguard In New Subscription Assault On Antibiotic Resistance

Deals Signed With UK’s NHS Pilot Scheme

Executive Summary

Two antibiotics from Pfizer and Shionogi are to be rolled out by the UK’s NHS in a pioneering subscription deal that hopes to encourage antibiotic R&D by delinking payment from volume of use.

You may also be interested in...



Japan Q2 Roundup: Mixed Bag For Majors But Forex Provides Boost

Japan's top pharma firms logged generally strong performances for mainstay global drugs in the fiscal period ended 30 September, with the weakened yen adding substantially to figures for those with large overseas sales. Astellas and Eisai are among those awaiting important global-first approvals for potential blockbusters.

Shionogi Reveals Strategy For COVID-19 Drug Xocova

Shionogi is hoping to demonstrate the efficacy of its oral COVID-19 candidate Xocova through an appropriate primary endpoint in its Phase III trial, while the Japanese firm is also eyeing global expansion for the drug should a world-first domestic approval be granted.

Boehringer Pledges Another €30m To Tackle AMR

The three companies have joined forces to launch Aurobac Therapeutics, combining their respective strengths to develop a precision approach to treating infections.

Related Content

Topics

Related Companies

Latest News
See All
UsernamePublicRestriction

Register

SC146562

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel